Antimetastatic Effect of Liposomal Recombinant Lactaptin

V. I. Kaledin, O. A. Koval, E. V. Kuligina, E. L. Lushnikova, V. P. Nikolin, N. A. Popova, I. A. Pyshnaya, V. A. Richter

Результат исследования: Научные публикации в периодических изданияхстатья

2 Цитирования (Scopus)

Аннотация

Antimetastatic effect of the liposomal form of recombinant lactaptin RL2 (a proteolytic fragment of human breast milk κ-casein; 8.6 kDa) was studied in A/Sn mice after intravenous transplantation of GA-1 tumor with high rate of liver metastases. Tumor growth in the liver was found in all mice. In animals dying early, the tumors were presented by multiple nodes of about the same size; in mice dying later, the tumors in the liver were presented by just few large nodes formed by cells that survived chemotherapy. A single intravenous injection of RL2 lactaptin in liposomes prolonged lifespan of animals with liver metastases of GA-1 tumor by 1.5 times in comparison with that in untreated animals.

Язык оригиналаанглийский
Страницы (с-по)762-765
Число страниц4
ЖурналBulletin of Experimental Biology and Medicine
Том164
Номер выпуска6
DOI
СостояниеОпубликовано - апр 2018

Fingerprint Подробные сведения о темах исследования «Antimetastatic Effect of Liposomal Recombinant Lactaptin». Вместе они формируют уникальный семантический отпечаток (fingerprint).

  • Цитировать

    Kaledin, V. I., Koval, O. A., Kuligina, E. V., Lushnikova, E. L., Nikolin, V. P., Popova, N. A., Pyshnaya, I. A., & Richter, V. A. (2018). Antimetastatic Effect of Liposomal Recombinant Lactaptin. Bulletin of Experimental Biology and Medicine, 164(6), 762-765. https://doi.org/10.1007/s10517-018-4075-0